<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="project_funders\PMC6305224\results\search\funders\results.xml">
  <result pre="mention of the Aeras transfer of its assets to the" exact="International AIDS Vaccine Initiative," post="in October 2018, is made In section 6d, clarification"/>
  <result pre="health organizations working on TB vaccines a. Perspectives from the" exact="Bill and Melinda Gates Foundation" post="b. The Global TB Vaccine Partnership c. Aeras d."/>
  <result pre="Foundation b. The Global TB Vaccine Partnership c. Aeras d." exact="European and Developing Countries Clinical Trials Partnership" post="e. The Stop TB Partnership, working group on new"/>
  <result pre="for new tuberculosis vaccines and landscape analysis a. Introduction The" exact="World Health Organization" post="(WHO) provides guidance on priority targets and development pathways"/>
  <result pre="by 2025 for the targets to be reached. The ongoing" exact="United Nations" post="(UN)–led efforts to prioritize action against TB is illustrated"/>
  <result pre="(Austria), Aeras, the South African TB Vaccine Initiative (SATVI), The" exact="European and Developing Countries Clinical Trials Partnership" post="(EDCTP) and the Research Council of Norway. H56:IC31 is"/>
  <result pre="(C57Bl6 mice). Utilizing a genome wide qRT-PCR platform developed at" exact="Stanford University," post="Mtb genes were selected that were persistently and highly"/>
  <result pre="(e.g., Peace Corps workers, persons entering service with Doctors without" exact="Borders" post="or other NGOs). Half will be will vaccinated with"/>
  <result pre="the Collaboration for TB Vaccine Development (CTVD), led by the" exact="Bill and Melinda Gates Foundation" post="(BMGF). CTVD recommendations regarding NHP-based study design for TB"/>
  <result pre="health organizations working on TB vaccines a. Perspectives from the" exact="Bill and Melinda Gates Foundation" post="The BMGF represents the largest global funder of research"/>
  <result pre="development of TB vaccines, had its assets transferred to the" exact="International AIDS Vaccine Initiative" post="as of October 2018. Aeras/IAVI representatives stressed that TB"/>
  <result pre="must be accepted if success is to be achieved. d." exact="European and Developing Countries Clinical Trials Partnership" post="The European and Developing Countries Clinical Trials Partnership (EDCTP)"/>
  <result pre="achieved. d. European and Developing Countries Clinical Trials Partnership The" exact="European and Developing Countries Clinical Trials Partnership" post="(EDCTP) funds clinical research to accelerate the development of"/>
  <result pre="is the collaboration between TuBerculosis Vaccine Initiative (TBVI), Aeras, the" exact="European Commission" post="(EC), BMGF and EDCTP in developing stage gate criteria,"/>
  <result pre="study of VPM 1002 in African infants (conducted by Vakzine" exact="Project Management," post="Hannover, Germany and the Serum Institute of India, Pune,"/>
  <result pre="and Tanzania (sponsored by the Statens Serum Institute and the" exact="International AIDS Vaccine Initiative" post="[IAVI]). Additionally, the EDCTP will help support development of"/>
  <result pre="for Infection Biology, Berlin, Germany); Small Animal Models: Andrea Cooper" exact="University of Leicester," post="Leicester, UK); The Role of a Continuous Exposure Natural"/>
  <result pre="not necessarily represent the decisions or the policies of the" exact="World Health Organization." post="References 1collab: Organisation mondiale de la santé: Global tuberculosis"/>
 </snippets>
</snippetsTree>
